Associations - EGFR exon 19 deletion

EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval	osimertinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline	osimertinib Sensitive: A2 - Guideline
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: B - Late Trials	EGFR inhibitor Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	icotinib Sensitive: B - Late Trials	icotinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + rivoceranib Sensitive: B - Late Trials	gefitinib + rivoceranib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials	bevacizumab + atezolizumab Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + ramucirumab Sensitive: B - Late Trials	gefitinib + ramucirumab Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR inhibitor Sensitive: B - Late Trials	EGFR inhibitor Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	aumolertinib Sensitive: B - Late Trials	aumolertinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	furmonertinib Sensitive: B - Late Trials	furmonertinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label	osimertinib Resistant: C1 - Off-label
EGFR exon 19 deletion EGFR exon 19 deletion	Small Cell Lung Cancer Small Cell Lung Cancer	EGFR exon 19 deletion EGFR exon 19 deletion	Small Cell Lung Cancer Small Cell Lung Cancer	gefitinib Sensitive: C1 - Off-label	gefitinib Sensitive: C1 - Off-label
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Cancer Lung Cancer	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Cancer Lung Cancer	gefitinib Sensitive: C1 - Off-label	gefitinib Sensitive: C1 - Off-label
EGFR exon 19 deletion EGFR exon 19 deletion	Small Cell Lung Cancer Small Cell Lung Cancer	EGFR exon 19 deletion EGFR exon 19 deletion	Small Cell Lung Cancer Small Cell Lung Cancer	osimertinib Sensitive: C1 - Off-label	osimertinib Sensitive: C1 - Off-label
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria	osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGF816 Sensitive: C2 – Inclusion Criteria	EGF816 Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw + lazertinib Sensitive: C2 – Inclusion Criteria	amivantamab-vmjw + lazertinib Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	U3-1402 Sensitive: C2 – Inclusion Criteria	U3-1402 Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: C2 – Inclusion Criteria	tislelizumab Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + anlotinib Sensitive: C3 – Early Trials	erlotinib + anlotinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	camrelizumab + rivoceranib Resistant: C3 – Early Trials	camrelizumab + rivoceranib Resistant: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib + DFP-14323 Sensitive: C3 – Early Trials	afatinib + DFP-14323 Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + durvalumab Resistant: C3 – Early Trials	gefitinib + durvalumab Resistant: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	bevacizumab + erlotinib Sensitive: C3 – Early Trials	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	olaparib + gefitinib Sensitive: C3 – Early Trials	olaparib + gefitinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	ensartinib Sensitive: C3 – Early Trials	ensartinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: C3 – Early Trials	brigatinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: C3 – Early Trials	alectinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: C3 – Early Trials	lorlatinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + fruquintinib Sensitive: C3 – Early Trials	gefitinib + fruquintinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	anlotinib + APL-502 Sensitive: C3 – Early Trials	anlotinib + APL-502 Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib + anlotinib Sensitive: C3 – Early Trials	gefitinib + anlotinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	bevacizumab + osimertinib Sensitive: C3 – Early Trials	bevacizumab + osimertinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	brigatinib Sensitive: C3 – Early Trials	brigatinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: C3 – Early Trials	durvalumab Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR inhibitor Sensitive: C3 – Early Trials	EGFR inhibitor Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	bevacizumab + gefitinib Sensitive: C3 – Early Trials	bevacizumab + gefitinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Thymic Carcinoma Thymic Carcinoma	EGFR exon 19 deletion EGFR exon 19 deletion	Thymic Carcinoma Thymic Carcinoma	icotinib Sensitive: C4 – Case Studies	icotinib Sensitive: C4 – Case Studies
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: C4 – Case Studies	bevacizumab + atezolizumab Sensitive: C4 – Case Studies
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ado-trastuzumab emtansine Sensitive: D – Preclinical	erlotinib + ado-trastuzumab emtansine Sensitive: D – Preclinical
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	lenalidomide Sensitive: D – Preclinical	lenalidomide Sensitive: D – Preclinical
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	CH7233163 Sensitive: D – Preclinical	CH7233163 Sensitive: D – Preclinical
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Cancer Lung Cancer	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Cancer Lung Cancer	BMS-722782 Sensitive: D – Preclinical	BMS-722782 Sensitive: D – Preclinical
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	H002 Sensitive: D – Preclinical	H002 Sensitive: D – Preclinical